Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CDC25A | P30304 | 1/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | CETP | P11597 | 3/20 | 0.50 |
| ▸ | FABP3 | P05413 | 1/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | PTAFR | P25105 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14000864 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL21580898 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL27699112 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL20482670 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL20483366 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL12235520 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL27542770 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL28786169 | 0.98 | LMNA (0.56) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL29267508 | 0.91 | LPAR3 (0.53) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL27747029 | 0.91 | LPAR3 (0.53) | LMNAESR1ADORA3CDC25AAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172846-A1 | ORAL DISSOLVABLE FILM AND METHOD OF MANUFACTURING AND USING THE SAME | CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V. (MX) | 2023-06-08 | — | — | US | disclosed |
| WO-2023088284-A1 | SELF-MICROEMULSION COMPOSITION AND PREPARATION AND USE THEREOF | 湖南慧泽生物医药科技有限公司 | 2023-05-25 | — | — | WO | disclosed |
| EP-4084781-A1 | ORAL DISSOLVABLE FILM AND METHOD OF MANUFACTURING AND USING THE SAME | TF Tech Ventures (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-114206916-A | Restricted peptides | 缇尔索卢森公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-113727700-A | Method for preparing stable peptide preparation | 伊莱利利公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2021138564-A1 | ORAL DISSOLVABLE FILM AND METHOD OF MANUFACTURING AND USING THE SAME | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2021-07-08 | — | — | WO | disclosed |
| US-20210183469-A9 | COMPUTATIONAL PLATFORM FOR IN SILICO COMBINATORIAL SEQUENCE SPACE EXPLORATION AND ARTIFICIAL EVOLUTION OF PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-17 | — | — | US | disclosed |
| CN-111432846-A | Semiconductor SWCNT dispersion for bioimaging and method for producing same | 株式会社岛津制作所 | 2020-07-17 | — | — | CN | disclosed |
| CN-111356481-A | Semiconductor SWCNT dispersion for bioimaging and method for examining the same | 株式会社岛津制作所 | 2020-06-30 | — | — | CN | disclosed |
| US-20200048636-A1 | IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-02-13 | — | — | US | disclosed |
| US-20190279741-A1 | COMPUTATIONAL PLATFORM FOR IN SILICO COMBINATORIAL SEQUENCE SPACE EXPLORATION AND ARTIFICIAL EVOLUTION OF PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-09-12 | — | — | US | disclosed |
| US-20170298094-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | TREVENA, INC. | 2017-10-19 | — | — | US | disclosed |
| CN-106139158-A | The growth hormone that in vivo efficacy extends | 诺沃—诺迪斯克保健股份有限公司 | 2016-11-23 | — | — | CN | disclosed |
| CN-104758253-A | Technology for preparation of macromolecular microspheres | NEXBIO INC | 2015-07-08 | — | — | CN | disclosed |
| CN-103784408-A | Technology for the preparation of microparticles | ANSUN BIOPHARMA INC | 2014-05-14 | — | — | CN | disclosed |
| CN-101848704-A | Techniques for preparing microparticles | NEXBIO INC | 2010-09-29 | — | — | CN | disclosed |
| CN-101404980-A | Preparation Technology of Macromolecular Microspheres | NEXBIO INC (US) | 2009-04-08 | — | — | CN | disclosed |
| CN-101060856-A | Soluble, stable insulin-containing formulations | NOVO NORDISK AS (DK) | 2007-10-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298094-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | ARRB1, ADRB1, ADRB3 | LMNA 1452/4885ESR1 3926/4885ADORA3 1166/4885 |
| US-20230172846-A1 | ORAL DISSOLVABLE FILM AND METHOD OF MANUFACTURING AND USING THE SAME | DSTN, FDFT1, DDHD2 | LMNA 4237/4885ESR1 3637/4885ADORA3 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.